These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18950288)

  • 1. Efficacy of rapamycin in scleroderma: a case study.
    Fried L; Kirsner RS; Bhandarkar S; Arbiser JL
    Lymphat Res Biol; 2008; 6(3-4):217-9. PubMed ID: 18950288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
    Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
    Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the immunosuppressant rapamycin on the expression of human α2(I) collagen and matrix metalloproteinase 1 genes in scleroderma dermal fibroblasts.
    Tamaki Z; Asano Y; Kubo M; Ihn H; Tada Y; Sugaya M; Kadono T; Sato S
    J Dermatol Sci; 2014 Jun; 74(3):251-9. PubMed ID: 24630239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Connective tissue metabolism including cytokines in scleroderma.
    Smith EA
    Curr Opin Rheumatol; 1992 Dec; 4(6):869-77. PubMed ID: 1457283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of dermal connective tissue in scleroderma.
    Kähäri VM
    Ann Med; 1993 Dec; 25(6):511-8. PubMed ID: 8292298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tropisetron suppresses collagen synthesis in skin fibroblasts via α7 nicotinic acetylcholine receptor and attenuates fibrosis in a scleroderma mouse model.
    Stegemann A; Sindrilaru A; Eckes B; del Rey A; Heinick A; Schulte JS; Müller FU; Grando SA; Fiebich BL; Scharffetter-Kochanek K; Luger TA; Böhm M
    Arthritis Rheum; 2013 Mar; 65(3):792-804. PubMed ID: 23440693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin.
    Kubo M; Czuwara-Ladykowska J; Moussa O; Markiewicz M; Smith E; Silver RM; Jablonska S; Blaszczyk M; Watson DK; Trojanowska M
    Am J Pathol; 2003 Aug; 163(2):571-81. PubMed ID: 12875977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of skin fibrosis in systemic sclerosis.
    Jinnin M
    J Dermatol; 2010 Jan; 37(1):11-25. PubMed ID: 20175837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic sclerosis: an update.
    Varga J
    Bull NYU Hosp Jt Dis; 2008; 66(3):198-202. PubMed ID: 18937632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD109 overexpression ameliorates skin fibrosis in a mouse model of bleomycin-induced scleroderma.
    Vorstenbosch J; Al-Ajmi H; Winocour S; Trzeciak A; Lessard L; Philip A
    Arthritis Rheum; 2013 May; 65(5):1378-83. PubMed ID: 23436317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma.
    Ghosh AK; Bhattacharyya S; Lakos G; Chen SJ; Mori Y; Varga J
    Arthritis Rheum; 2004 Apr; 50(4):1305-18. PubMed ID: 15077315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Transforming growth factor-beta and its receptors in scleroderma].
    QIAN H; ZHENG M
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Jul; 38(4):415-21. PubMed ID: 19693982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokines and human fibrosis.
    LeRoy EC; Trojanowska MI; Smith EA
    Eur Cytokine Netw; 1990; 1(4):215-9. PubMed ID: 1966552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained activation of fibroblast transforming growth factor-beta/Smad signaling in a murine model of scleroderma.
    Takagawa S; Lakos G; Mori Y; Yamamoto T; Nishioka K; Varga J
    J Invest Dermatol; 2003 Jul; 121(1):41-50. PubMed ID: 12839562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scar wars: is TGFbeta the phantom menace in scleroderma?
    Leask A
    Arthritis Res Ther; 2006; 8(4):213. PubMed ID: 16774692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vertical inhibition of PI3K/Akt/mTOR signaling demonstrates in vitro and in vivo anti-fibrotic activity.
    Liang M; Lv J; Chu H; Wang J; Chen X; Zhu X; Xue Y; Guan M; Zou H
    J Dermatol Sci; 2014 Nov; 76(2):104-11. PubMed ID: 25258031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel treatment approaches to fibrosis in scleroderma.
    Distler J; Distler O
    Rheum Dis Clin North Am; 2008 Feb; 34(1):145-59; vii. PubMed ID: 18329537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist.
    Cipriani P; Di Benedetto P; Ruscitti P; Capece D; Zazzeroni F; Liakouli V; Pantano I; Berardicurti O; Carubbi F; Pecetti G; Turricchia S; Alesse E; Iglarz M; Giacomelli R
    J Rheumatol; 2015 Oct; 42(10):1808-16. PubMed ID: 26276964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of the immunosuppressant FK-506 on human alpha2(I) collagen gene expression and transforming growth factor beta signaling in normal and scleroderma fibroblasts.
    Asano Y; Ihn H; Yamane K; Jinnin M; Mimura Y; Tamaki K
    Arthritis Rheum; 2005 Apr; 52(4):1237-47. PubMed ID: 15818662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
    Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
    Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.